Could This Ancient Herb Be the Key to Easing Arthritis?
"New research highlights the potential of Polyphyllin I in alleviating inflammation and joint damage associated with collagen-induced arthritis."
Rheumatoid arthritis (RA) is a chronic autoimmune condition affecting millions worldwide, marked by persistent joint inflammation that can lead to cartilage and bone damage. Current treatments primarily focus on managing symptoms, often with significant side effects, leading researchers to explore alternative and complementary therapies.
Macrophages, a type of immune cell, play a central role in the development and progression of RA. In RA, an increased number of M1-like macrophages infiltrate the joints, releasing pro-inflammatory cytokines that exacerbate inflammation and tissue damage. Targeting these macrophages and the inflammatory pathways they activate has become a focal point in RA research.
A recent study published in Frontiers in Immunology sheds light on a promising natural compound called Polyphyllin I (PPI). Found in the Rhizoma of Paris polyphyllin plant, traditionally used in Chinese medicine, PPI has demonstrated selective inhibitory effects on various tumor cells. Now, scientists are exploring its potential in managing rheumatoid arthritis by suppressing inflammation in macrophages.
How Common Is Arthritis?
In the United States, 21.6% of adults age 18 and older had diagnosed arthritis in 2022, according to CDC data. The CDC also reports 9.9 million office-based physician visits with osteoarthritis as the primary diagnosis. Separately, The Global Statistics reports that rheumatoid arthritis affects approximately 1.3 million U.S. adults; this is a figure for rheumatoid arthritis, not all arthritis.
Treating RA and Its Complexity
The National Center for Complementary and Integrative Health says rheumatoid arthritis treatment usually includes medications to slow the disease and prevent joint deformity, alongside self-management strategies to reduce pain and disability. A review describes RA as a multifactorial autoimmune disease of unknown etiology, with an incompletely understood pathophysiology. Given this complexity, the review says good management requires a multidisciplinary approach.
From Traditional Remedies to Targeted Treatment
Past treatments for rheumatoid arthritis included cold therapy, bloodletting, and willow bark. A historical review traces drug therapy’s evolution over five decades, from empirical symptom relief with salicylates toward targeted intervention. This history reflects a complex evolution in RA treatment rather than a single discovery.
How Does Polyphyllin I Fight Inflammation in Arthritis?
The Frontiers in Immunology study thoroughly investigated the effects of PPI on macrophages, both in vitro (in lab settings) and in vivo (in a collagen-induced arthritis mouse model). Researchers examined how PPI influences the inflammatory response in macrophages stimulated by lipopolysaccharide (LPS) and interferon-gamma (IFN-γ), two substances known to trigger inflammation.
- Reducing the production of inflammatory cytokines (IL-1β, IL-6, TNF-α)
- Inhibiting the phosphorylation of IKKα/β and p65, key proteins in the NF-κB pathway
- Preventing the translocation of p65 into the nucleus, where it activates gene expression
What Recent Reviews Are Examining
A Nature Reviews Rheumatology item dated September 3, 2026, reports research suggesting that tissue-resident macrophages occupy a fibrin-rich niche and actively remodel the synovial lining in rheumatoid arthritis. The Nature rheumatoid arthritis research page also describes a review of the pathophysiology of lung involvement and common forms of RA-associated pulmonary disease. Separately, the listed randomized pilot study is titled “A Randomized, Pilot Study to Assess the Efficacy and Safety of Curcumin in Patients with Active Rheumatoid Arthritis”; its supplied excerpt describes standard RA drug regimens but does not report the study’s results.
Limits in the Evidence for Supplements
In a phase III, double-blind, randomized trial, curcumin did not improve flare-free survival among patients with RA in remission who were tapering conventional synthetic DMARDs, despite adequate serum levels; the trial was registered as CTRI/2018/04/013279. A separate double-blind pilot study of H15, a Boswellia serrata resin extract, had only 37 patients available for detailed efficacy and safety analysis—18 receiving the extract and 19 placebo. The supplied H15 excerpt gives the analysis size but does not report its efficacy or safety findings.
Tripterygium Compared with Methotrexate
The TRIFRA randomized controlled clinical trial compared Tripterygium wilfordii Hook F (TwHF) with methotrexate (MTX) in active rheumatoid arthritis, including a group receiving both treatments. In the intention-to-treat analysis, ACR50 response rates were 46.4% (32/69) for MTX, 55.1% (38/69) for TwHF, and 76.8% (53/69) for the combination. The reported comparisons with MTX monotherapy were statistically significant for TwHF (p=0.014) and MTX plus TwHF (p<0.001).
What Does This Mean for Arthritis Sufferers?
This research suggests that Polyphyllin I holds promise as a therapeutic agent for rheumatoid arthritis. By targeting the NF-κB pathway in macrophages, PPI can effectively reduce inflammation and prevent joint damage, potentially slowing the progression of the disease. However, it's important to note that this study was primarily conducted in vitro and in animal models. Further research, including clinical trials in humans, is needed to confirm these findings and determine the optimal dosage and safety of PPI for RA treatment. While more studies are underway, PPI presents a new possible method for treatment of RA.
Personalized Approaches on the Horizon
A July 11, 2024, review titled “Rheumatoid Arthritis: Current Treatments and Future Outlook” discusses emerging trends in RA therapy, including personalized approaches guided by biomarkers. It also notes that traditional treatments, including DMARDs, often fail, leaving some patients without adequate options. A June 24, 2025, article similarly presents personalized therapies and holistic approaches as areas of interest for future RA care.
Patients in Real-World Care
A 2025 study of targeted therapy in RA used data from the FIRST registry, a multicenter cohort of patients treated with biologic or targeted synthetic DMARDs, and describes management challenges over 20 years using a cohort from the world’s oldest society. A separate Thermo Fisher case study profiles Emma, age 32, who had existing foot and hand pain and sought care after three months of hand pain, neck stiffness, and worsening fatigue. These sources offer, respectively, a cohort-based view of treatment and an individual patient example.